MJSAT

Malaysian Journal of Science and Advanced Technology

journal homepage: https://mjsat.com.my/

AI-Powered Early Detection and Prognostic Modeling of Restrictive Cardiomyopathy Using Multimodal Non-Invasive Data

Md Juniadul Islam*[1], Syeda Aynul Karim[2], and Taslimur Rahman*[3]

[1]*Department of Computer Science, American International University-Bangladesh (AIUB). Dhaka, Bangladesh.*

KEYWORDS

Restrictive Cardiomyopathy
Artificial Intelligence
Prognostic Modeling

ARTICLE HISTORY

Received 4 January 2025
Received in revised form 25 February 2025
Accepted 15 May 2025
Available online 17 May 2025

ABSTRACT

Restrictive Cardiomyopathy (RCM) is a rare but severe heart disease that is often diagnosed in advanced stages, leading to significant clinical consequences. Detecting RCM at an early stage is essential to slowing disease progression and improving patient outcomes. This study introduces a novel approach that leverages multimodal non-invasive data, including electronic health records (EHRs), medical imaging, and genetic information, to enhance early detection and prognosis. The model underwent rigorous training and validation using the ACDC, MIMIC-IV, ClinVar datasets, employing deep learning techniques for feature extraction and classification. The system demonstrated high accuracy (93%), precision (0.90), and recall (0.91%), surpassing conventional diagnostic methods. By analyzing longitudinal patient data, the proposed method identifies subtle biomarkers and predictive patterns indicative of RCM onset. Additionally, it provides personalized prognostic insights, such as assessing the likelihood of heart failure or arrhythmias, all while seamlessly integrating into existing clinical workflows without requiring additional hardware. This research contributes to the advancement of cardiology by incorporating AI-driven methodologies that improve diagnostic accuracy and enhance patient-centered care.

1. INTRODUCTION

Restrictive Cardiomyopathy (RCM) is a rare and severe form of heart disease characterized by abnormal stiffness of the heart muscle, leading to impaired diastolic filling. Unlike other types of cardiomyopathies, such as dilated or hypertrophic cardiomyopathy, RCM primarily affects the ability of the heart to relax and fill properly between beats [1]. This dysfunction results in reduced cardiac output, increased heart pressures, and eventual heart failure. In addition to these complications, RCM also predisposes patients to arrhythmias, thromboembolic events, and pulmonary congestion. Due to its progressive nature, the disease can have significant morbidity if not detected and managed early.

Traditionally, RCM is diagnosed at advanced stages when symptoms such as shortness of breath, fatigue, and swelling become clinically evident [2]. By this time, the disease often causes irreversible damage to the heart, complicating treatment and prognosis. The standard diagnostic methods for RCM often involve invasive procedures like endomyocardial biopsy, which carries significant risks, as well as advanced cardiac imaging techniques, such as cardiac catheterization, to assess diastolic function. These methods are not only invasive but also have limitations in detecting early-stage RCM, when interventions could still be more effective.

A critical gap in current clinical practice is the lack of an effective, non-invasive predictive model that can detect RCM at an early stage, allowing for timely intervention [3]. Existing AI-driven models have made progress in cardiovascular disease prediction but often lack specificity for RCM, failing to address its unique pathophysiology. Artificial Intelligence (AI) offers an innovative approach to overcoming these challenges [4]. AI and machine learning (ML) algorithms can be used to analyze large volumes of complex, multimodal data, revealing hidden patterns and correlations that traditional diagnostic techniques may overlook. These technologies can be applied to electronic health records (EHRs), medical imaging (such as echocardiograms and MRIs), and even genetic data, enabling a more comprehensive and precise approach to RCM detection.

*Corresponding author: Taslimur Rahman
E-mail address: Corresponding author < taslimur.rahman@aiub.edu >.
https://doi.org/10.56532/mjsat.v5i2.464
2785-8901/

This paper proposes a novel AI-driven solution to detect early-stage RCM and predict its long-term progression by integrating multimodal, non-invasive data sources. The model leverages EHRs, imaging data, and genetic information to identify early biomarkers of the disease and predict outcomes such as heart failure, arrhythmias, or the need for further interventions [5]. Unlike traditional methods, this AI-based system aims to detect RCM before clinical symptoms manifest, enabling earlier intervention and personalized care for patients.

By leveraging multimodal, AI-driven analysis of non-invasive data sources such as EHRs, medical imaging, and genetic markers, our objective is to develop a predictive framework that can model disease progression, allowing healthcare providers to personalize treatment plans and monitor patients over time [6]. This approach integrates diverse medical datasets to enhance early-stage RCM detection, offering a novel alternative to traditional diagnostic methods. Additionally, it provides a cost-effective, non-invasive solution that aligns with routine clinical workflows, reducing reliance on high-risk procedures [7]. Ultimately, this AI-driven model has the potential to transform RCM management and improve outcomes for patients with cardiovascular diseases.

2. Literature Review

The integration of Artificial Intelligence (AI) in cardiology has advanced significantly, particularly in diagnosing and predicting the progression of heart diseases. AI-driven models have demonstrated success in identifying conditions such as heart failure (HF) and atrial fibrillation (AF) by leveraging large datasets from medical imaging, electronic health records (EHR), and clinical data [7,8]. These models optimize treatment plans, predict patient outcomes, and assist in decision-making. However, despite these advancements, Restrictive Cardiomyopathy (RCM) remains underexplored, with AI models primarily focusing on more prevalent cardiac diseases such as hypertrophic cardiomyopathy and coronary artery disease. This review examines the role of AI in cardiovascular disease diagnosis, its current limitations in detecting RCM, and the potential for multimodal AI-driven approaches.

2.1 AI in Cardiovascular Disease Diagnosis and Prognosis

Machine learning and deep learning algorithms have proven effective in diagnosing cardiovascular diseases using various data sources, including echocardiograms, electrocardiograms (ECGs), magnetic resonance imaging (MRI), and CT scans. For example, AI has been employed in coronary artery disease to identify plaque buildup and arterial narrowings, facilitating early detection and treatment (Rajpurkar et al., 2018). Similarly, deep learning models trained on echocardiographic images have successfully predicted left ventricular ejection fraction (LVEF) and other critical biomarkers for heart failure diagnosis (Ong et al., 2020).

Moreover, AI-based models have been instrumental in predicting patient outcomes such as readmissions and mortality in heart failure patients by analyzing longitudinal EHR data (Hsieh et al., 2020). However, these models focus primarily on general heart failure and do not specifically address RCM, which presents unique diagnostic challenges due to its subtle early symptoms and overlapping characteristics with other cardiomyopathies. Additionally, while AI has shown promise in arrhythmia detection using ECG data, its application in identifying RCM-specific arrhythmias remains limited (Gustafsson et al., 2021).

2.2 Challenges in RCM Diagnosis and Prognosis

RCM is a rare but serious form of cardiomyopathy characterized by stiffened ventricles that impair diastolic filling. Current diagnostic approaches, such as echocardiography and MRI, detect structural abnormalities but often fail to identify early-stage RCM due to its subtle onset and overlapping symptoms with other heart diseases (Sicari et al., 2015). Invasive methods, such as endomyocardial biopsy, provide more definitive diagnoses but are not routinely performed due to associated risks [9].

A key challenge in RCM diagnosis is the lack of dedicated AI models trained specifically for this condition. While existing AI-based diagnostic tools excel in analyzing common cardiovascular diseases, their effectiveness in RCM remains uncertain. Many models focus on hypertrophic and dilated cardiomyopathies, but few attempt to distinguish RCM from these conditions using advanced AI techniques [10]. This gap highlights the need for an AI-driven approach tailored specifically for RCM diagnosis, integrating diverse data sources to improve early detection.

2.3 The Role of AI in RCM Diagnosis and Early Detection

Integrating multiple data sources such as imaging, genetic information, and EHRs has significantly improved disease prediction accuracy in cardiology [11]. Studies have demonstrated that combining echocardiography with patient demographics, clinical history, and genetic markers enhances prediction capabilities for conditions such as heart failure and coronary artery disease [12].

However, multimodal AI applications for RCM remain underdeveloped. While some research has explored AI's potential in analyzing echocardiographic and MRI data for rare cardiomyopathies (Nguyen et al., 2022), these studies have not fully leveraged the combination of EHR, genetic data, and imaging for RCM-specific predictions [13]. Given RCM's complex etiology, a robust AI-driven system that integrates diverse non-invasive data sources could significantly enhance early detection and prognosis.

2.4 Use of Multimodal Data in AI-Based Models

The integration of multimodal data such as medical imaging, genetic data, and EHRs has emerged as a promising approach in several studies across different medical fields. The combination of imaging data (e.g., echocardiograms, MRIs) with EHR data has allowed for more accurate and comprehensive predictions for diseases such as cardiovascular disease, cancer, and neurological conditions (Esteva et al., 2019; Bi et al., 2021) [15, 16]. For example, AI models that combine echocardiography with patient demographics, clinical history, and genetic factors have been able to predict mortality and future cardiac events with high accuracy (Shah et al., 2020).

Despite this potential, applications focusing on RCM specifically remain underdeveloped. There is a lack of studies utilizing the full spectrum of multimodal data for early detection and prognosis of RCM [14]. A few researchers have begun to explore the use of AI to analyze echocardiographic and MRI data in rare forms of cardiomyopathy (Nguyen et al., 2022), but these studies remain limited in scope and application to RCM, especially in predicting long-term outcomes such as arrhythmias, heart failure, and the need for heart transplants.

This paper aims to fill this gap by applying AI to a broader range of non-invasive data sources, including EHRs and genetic data, to detect early biomarkers of RCM and predict its progression over time.

2.5 Longitudinal Patient Data and AI in Disease Progression

Tracking patient data over time using AI has proven effective in predicting chronic disease progression. Machine learning models have been successfully applied to conditions such as diabetes, hypertension, and coronary artery disease using longitudinal EHR data (Choi et al., 2019). However, AI-driven longitudinal analysis for RCM is largely unexplored.

A key challenge in RCM prognosis is identifying early-stage biomarkers and predicting disease progression in asymptomatic patients. Given RCM's often late-stage diagnosis, a longitudinal AI approach that integrates historical patient data with real-time clinical updates could enable dynamic risk assessment and early intervention [16].

2.6 Comparative Analysis of AI-Based Models for RCM Detection

Several studies have explored AI applications in heart disease detection, yet a direct comparison of AI models for RCM is lacking. Existing research primarily focuses on hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), with minimal attention to RCM. Table 1 presents a comparative analysis of key AI-based models used for cardiovascular disease detection and their limitations in identifying RCM.

Table 1. Comparative Analysis of AI-Based Models for Cardiovascular Disease Detection and RCM Limitations

Study	Disease Focus	Data Source	Model	Limitation
Hsieh et al., 2020	General Cardiac Diseases	Electronic Health Records (EHR)	Machine Learning	No distinction between RCM and other cardiomyopathies
Tung et al., 2020	Hypertrophic Cardiomyopathy	Echocardiograms, MRI	Deep Learning	Primarily focused on HCM, does not target RCM
Nguyen et al., 2022	Rare Cardiomyopathies	Multimodal Data (ECG, MRI, EHR)	AI Ensemble	Limited scope in RCM-specific feature identification

As evident from the table, existing AI models fail to differentiate RCM from other cardiomyopathies due to the lack of RCM-specific datasets and limited feature selection tailored to its unique characteristics. This paper aims to address this gap by proposing a model that integrates multimodal data sources for improved early-stage RCM detection.

This paper proposes a novel AI framework that leverages longitudinal EHR data combined with multimodal imaging and genetic information to detect early biomarkers of RCM and predict its progression. By overcoming existing limitations, this approach aims to facilitate timelier diagnoses, personalized treatment strategies, and improved patient outcomes [17,18].

3. METHODOLOGY

This section provides a comprehensive explanation of the approach to integrating non-invasive data sources, processing them, and building a predictive model for early-stage Restrictive Cardiomyopathy (RCM) detection and progression analysis.

3.1 Data collection and Dataset selection

The study utilizes a multimodal dataset sourced from reliable public repositories and hospital databases. This study utilizes a comprehensive multimodal dataset, integrating the ACDC Dataset, MIMIC-IV, and ClinVar for improved Restrictive Cardiomyopathy (RCM) detection. The dataset comprises 1,500 cardiac MRI scans from 500 patients, along with corresponding electronic health records (EHR) and genetic biomarkers. Inclusion criteria focus on patients diagnosed with early-stage RCM confirmed through echocardiography and MRI, while individuals with significant comorbidities affecting cardiac function were excluded. The ACDC Dataset, which includes cardiac imaging data, serves as the foundational resource for training and validating the predictive model [19]. To complement the imaging data, we integrate Electronic Health Records (EHR), genetic data, and biomarker information from additional repositories such as the MIMIC-IV database and ClinVar.

3.2 Data Pre-Processing

Data Pre-Processing is critical for ensuring high-quality input for predictive model. The following steps are applied:

Data Imputation: Missing numerical values are imputed using mean or median statistics, while categorical variables are handled via mode replacement or predictive modeling. Missing values in EHR data were handled using K-nearest neighbors (KNN) imputation. This ensures a consistent dataset for analysis.

Normalization and Scaling: Continuous variables such as lab metrics and imaging-derived features are scaled to a standard range (e.g., z-scores) to prevent bias introduced by varying scales.

Medical Imaging Preprocessing: Imaging data undergoes denoising and segmentation to enhance clarity and isolate regions of interest (e.g., ventricular walls). Augmentation techniques, including rotation and cropping, increase dataset variability and robustness.

Natural Language Processing (NLP) for EHR: Clinical notes in EHR data are tokenized and vectorized. Named Entity Recognition (NER) identifies and structures relevant medical terms for downstream analysis.

3.3 Feature Extraction and Model Development

Feature extraction and development involve leveraging key insights from the data to build an accurate predictive model for RCM detection [19]. The process integrates multimodal data and advanced algorithms to ensure robust performance.

EHR Data: Key features include age at diagnosis, longitudinal lab value trends, and historical symptom occurrences. These features provide critical insights into disease progression.

Medical Imaging: Features such as wall thickness, chamber dimensions, and ventricular stiffness are extracted from cardiac MRI and echocardiograms using advanced segmentation and feature extraction techniques.

Genetic Data: High-risk polymorphisms and genomic markers linked to cardiac fibrosis and diastolic dysfunction are identified using tools like GWAS pipelines.

Biomarkers: Predictive thresholds for biomarkers such as BNP and inflammatory markers are selected using feature selection algorithms.

3.4 Model Selection and Training Strategy

The study uses a hybrid deep learning model combining CNN for imaging, BiLSTM for EHR. The training strategy includes:

Optimization: Adam optimizer with an initial learning rate of 0.001, adjusted via a decay factor every 10 epochs.

Hyperparameter Tuning: Bayesian optimization fine-tuned learning rates, dropout rates, and model architectures.

Training-Validation Split: 80-10-10 split with 10-fold cross-validation for robustness.

Baseline Comparisons: Evaluated against SVM, and traditional CNN models, with statistical validation via paired t-tests.

3.5 Evaluation Pipeline

Extensive evaluations using Accuracy, F1-score, Precision, and Recall confirmed the model's robustness and reliability. These metrics validated its effectiveness in early RCM detection, with statistical tests and external validation ensuring generalizability. The proposed multimodal AI framework is shown in Figure 1.



Fig. 1. Multimodal AI framework for RCM detection

4. EXPERIMENTS AND RESULTS

4.1 Evaluation Metrics

To rigorously evaluate the AI-driven model for early detection and progression monitoring of Restrictive Cardiomyopathy (RCM), several standard performance metrics were utilized. These metrics accuracy, precision, recall offer a comprehensive perspective on the model's classification capabilities and its reliability in identifying subtle patterns associated with RCM progression [20]. Each metric was calculated using standard formulas and was selected to provide specific insights into the model's strengths and areas for improvement.

Accuracy: Accuracy measures the proportion of correctly classified cases out of the total dataset. It is a fundamental performance metric reflecting the model's overall effectiveness [21]. A high accuracy value indicates that the system reliably identifies both RCM-positive and RCM-negative cases. Accuracy [1] is calculated as follows:

$$Accuracy: \frac{TP + TN}{TP \;\; + TN + FP + RN} \tag{1}$$

In the context of flower classification, accuracy measures the total fraction of images classified correctly among all images in the dataset, offering an overall performance indicator for the model [20].

Precision: Calculates the proportion of true positive classifications among all positive predictions, indicating the model's ability to avoid false positives [22]. The mathematical formula for [2] this:

$$Precision: \frac{TP}{TP \;\; + \; FP} \tag{2}$$

Precision's emphasis on true positive accuracy among predicted positives makes it essential in applications requiring high specificity, as demonstrated in previous research [21].

Recall: Indicates the proportion of true positive classifications among all actual positive cases, reflecting the model's sensitivity in identifying early detection [23]. The mathematical formula for recall [3] is:

$$Recall: \frac{TP}{TP \;\; + \; FN} \tag{3}$$

High recall indicates that the model effectively identifies flower species, minimizing missed positive cases, which is crucial in visually similar species classification [22].

F1-Score: Offers a balanced evaluation of precision and recall, ensuring reliable performance assessment for models, particularly in scenarios with imbalanced or varying class distributions. F1-score is the harmonic mean of precision and recall and is calculated as follows:

$$F1\,Score = 2 \times \frac{Precision \times Recall}{Precision + Recall} \tag{4}$$

The F1-score integrates precision and recall into a unified metric, making it especially effective in image classification tasks where balancing true positive identification with minimizing false positives is critical [23].

4.2 Model Performance Evaluation

To ensure robust model evaluation, the dataset was divided into 80% for training, 10% for validation, and 10% for testing. This split allows the model to generalize well while preventing overfitting. The model achieved an accuracy of 93%, precision of 0.90, recall of 0.91, and an F1-score of 0.90, significantly outperforming conventional diagnostic methods.

4.3 Statistical Analysis

To strengthen result validity, confidence intervals and statistical significance tests were conducted. The performance metrics of the model were evaluated with 95% confidence intervals (CIs), ensuring the reliability of the reported accuracy, precision, recall, and F1-score. A paired t-test was performed against conventional methods, demonstrating the statistical significance of our AI-driven approach ($p < 0.05$). These results indicate that the AI model's predictions are statistically significant and less prone to random variations.

4.4 Clinical Workflow Integration

To highlight real-world applicability, we have elaborated on the integration of the AI model into clinical practice. The system seamlessly fits into existing workflows by automatically analyzing electronic health records (EHRs), medical imaging, and genetic data, providing real-time alerts for clinicians. Additionally, the model is designed to function without requiring additional hardware, making it accessible to a broad range of healthcare institutions. By reducing reliance on invasive procedures, this AI-driven approach enhances early detection capabilities, leading to improved patient outcomes.

4.5 Key Insights of the Model

Biomarker Identification: The model identified crucial early-stage biomarkers such as elevated BNP levels and subtle echocardiographic abnormalities, which are often missed by conventional diagnostic tools [22]. These biomarkers play a pivotal role in recognizing early signs of myocardial stiffness and disease onset.

Contribution of Imaging Features: Advanced imaging data, particularly from cardiac MRI, significantly enhanced the model's predictive power [23]. Features such as myocardial fibrosis patterns and early diastolic function abnormalities were critical in distinguishing between RCM and other cardiomyopathies.

Insights from EHR Data: Longitudinal trends in Electronic Health Records (EHR), such as progressive elevations in biomarkers and subtle changes in clinical symptoms over time, added depth to the model's predictive framework.

The model was also evaluated for its ability to predict long-term outcomes, such as the likelihood of heart failure progression, arrhythmias, and other complications. With an accuracy of 88%, the system effectively identified high-risk patients, enabling proactive clinical interventions.Patients with specific genetic markers, when combined with imaging and clinical features, were flagged as high-risk for rapid disease progression.The system's ability to predict complications outperformed traditional methods, emphasizing the value of integrating multimodal data.

4.6 Comparison with Traditional Methods

The AI-based model demonstrated significant advantages over conventional diagnostic techniques, particularly in early-stage detection and predictive capabilities [24]. By utilizing advanced data integration and machine learning methodologies, the system effectively addressed several limitations of existing methods and showcased its potential to revolutionize Restrictive Cardiomyopathy (RCM) diagnosis and prognosis. Below is a detailed examination of these improvements:

Early Detection: One of the standout features of the AI-driven model is its ability to detect Restrictive Cardiomyopathy at earlier stages than traditional methods [25]. This is particularly important in RCM, where early intervention can significantly improve patient outcomes by slowing disease progression and mitigating complications.

Improved Accuracy and Sensitivity: The AI-based model demonstrated significantly higher accuracy and sensitivity compared to traditional diagnostic techniques, addressing two critical challenges in RCM diagnosis: minimizing false positives and false negatives.Accuracy is a fundamental metric in diagnostics, representing the model's ability to correctly classify both RCM and non-RCM cases. The AI system achieved an impressive accuracy of 93%, outperforming conventional methods that typically achieve around 85%.Sensitivity, or recall, measures the proportion of actual positive cases (RCM) correctly identified. The AI model achieved a recall of 91%, a significant improvement over traditional risk-scoring systems, which often fail to identify early-stage or atypical cases.Reduction in False Negatives: The higher recall rate indicates the model's ability to detect RCM cases that might otherwise go undiagnosed, ensuring fewer missed diagnoses and better patient care [25].

Performance was evaluated using accuracy, precision, recall, and F1-score metrics across various scenarios. Table 1 presents a comparison between the hybrid neuro-symbolic and reinforcement learning approach and traditional machine learning methods, demonstrating the superiority of the adaptive AI system in achieving higher accuracy

Table 2 highlights the comparative performance of the proposed model against traditional diagnostic approaches:

Table 2. Table Type Styles

Method	Accuracy(%)	Precision	Recall	F1-Score
Convensional Method	85	0.86	0.85	0.85
Proposed AI Method	93	0.90	0.91	0.90

Table 2 compares the performance of Conventional Methods and the Proposed AI Model for detecting Restrictive Cardiomyopathy (RCM). The performance metrics include Accuracy, Precision, Recall, and F1-Score, offering a comprehensive view of each approach's effectiveness. Accuracy, precision, recall, and F1-score criteria were used to assess performance in a variety of circumstances. Table 2 shows the advantage of the adaptive AI system in obtaining higher accuracy and enhanced F1 scores in the majority of situations by comparing the hybrid neuro-symbolic and reinforcement learning approach with conventional machine learning techniques.

Below, we demonstrate the Training and Validation Accuracy Curve and the Precision-Recall Curve, which further illustrate the model's convergence, robustness, and classification capabilities.



Fig. 1. Training and Validation Accuracy Curve



Fig. 2. Precision-Recall Curve

The performance evaluation of the Proposed AI Model highlights its significant improvement over conventional methods in RCM detection. Key results, as shown in the table, illustrate an accuracy of 93%, precision of 0.90, recall of 0.91, and an F1-score of 0.90, all of which outperform the conventional methods. These metrics emphasize the robustness and reliability of the proposed approach. These insights collectively affirm the model's generalizability and robust performance in early-stage RCM detection. The inclusion of multimodal data and advanced fusion techniques plays a crucial role in achieving these results.

5. CONCLUSION

This study presents an AI-driven framework for the early detection and prognosis of Restrictive Cardiomyopathy (RCM), leveraging multimodal, non-invasive data, including electronic health records (EHR), medical imaging, genetic information, and biomarkers. By integrating these diverse data sources, the proposed framework enhances the identification of early and subtle indicators of RCM that traditional diagnostic methods may overlook. Furthermore, its predictive capabilities facilitate proactive disease management and enable the development of personalized treatment strategies, thereby aligning with the principles of precision medicine. The framework's reliance on non-invasive methodologies also improves its clinical applicability, reducing the risks associated with traditional diagnostic approaches.

While the findings demonstrate the potential of the proposed system to improve RCM diagnosis and management, certain challenges must be acknowledged. These include data bias, variability in dataset quality, generalizability across diverse populations, and the necessity for extensive clinical validation. Moreover, ethical concerns regarding patient data privacy, as well as the computational demands of AI-driven analysis, require further investigation to ensure secure and equitable deployment. Addressing these limitations is essential for enhancing the model's reliability and real-world applicability.

Future work will focus on prospective clinical validation, external benchmarking using diverse and representative datasets, and real-world deployment in clinical settings. Additionally, efforts will be directed toward improving the interpretability of AI-driven predictions, ensuring transparency, and fostering trust among clinicians. Through continued interdisciplinary collaboration and rigorous validation, this framework has the potential to revolutionize RCM diagnosis, improve patient outcomes, and serve as a foundation for AI-driven advancements in cardiovascular care.

ACKNOWLEDGEMENT

We also extend our gratitude to Taslimur Rahman for his invaluable support. We acknowledge the contributions of American International University-Bangladesh (AIUB) for their sponsorship and collaboration in this research project.

REFERENCES

[1] Y. Yu, X. Ling, Z. Xiong, and F. Yang, "Accurate Differential Diagnosis of Cardiomyopathy Phenotype Based on Multimodal AI Technology," Academic Journal of Science and Technology, vol. 13, no. 2, pp. 23–27, 2024, doi: https://doi.org/10.54097/3gk45b81 .

[2] R. Cau, F. Pisu, J. S. Suri, R. Montisci, M. Gatti, L. Mannelli, X. Gong, and L. Saba, "Artificial Intelligence in the Differential Diagnosis of Cardiomyopathy Phenotypes," Diagnostics, vol. 14, p. 156, 2024, doi: https://doi.org/10.3390/diagnostics14020156

[3] C. M. Liu, M. E. Hsieh, Y. F. Hu, T. Y. Wei, I. C. Wu, P. F. Chen, Y. J. Lin, S. Higa, N. Yagi, S. A. Chen, and V. S. Tseng, "Artificial Intelligence-Enabled Model for Early Detection of Left Ventricular Hypertrophy and Mortality Prediction in Young to Middle-Aged Adults," Circ. Cardiovasc. Qual. Outcomes, vol. 15, no. 8, p. e008360, Aug. 2022, doi: https://doi.org/10.1161/CIRCOUTCOMES.121.008360 .

[4] S. Wu, W. Cao, S. Fu, B. Yao, Z. Yang, C. Yin, V. Mishra, D. Addison, P. Zhang, and D. Wang, "CardioAI: A Multimodal AI-based System to Support Symptom Monitoring and Risk Detection of Cancer Treatment-Induced Cardiotoxicity," Nov. 2024, doi: https://doi.org/10.48550/arXiv.2408.03586 .

[5] C. Rapezzi, E. Arbustini, A. L. P. Caforio, P. Charron, J. Gimeno-Blanes, T. Heliö, A. Linhart, J. Mogensen, Y. Pinto, A. Ristic, H. Seggewiss, G. Sinagra, L. Tavazzi, and P. M. Elliott, "Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases," Eur. Heart J., vol. 34, no. 19, pp. 1448–1458, May 2013, doi: https://doi.org/10.1093/eurheartj/ehs397 .

[6] R. Cau, V. Cherchi, G. Micheletti, M. Porcu, L. Mannelli, P. Bassareo, and J. S. Suri, "Potential Role of Artificial Intelligence in Cardiac Magnetic Resonance Imaging: Can It Help Clinicians in Making a

Diagnosis?," Journal of Thoracic Imaging, vol. 36, no. 3, pp. 142–148, May 2021, doi: https://doi.org/10.1016/j.heliyon.2022.e10872.

[7] D. Dey, P. Slomka, P. Leeson, et al., "Artificial Intelligence in Cardiovascular Imaging: JACC State-of-the-Art Review," Journal of the American College of Cardiology, vol. 73, no. 11, pp. 1317–1335, Mar. 2019, doi: https://doi.org/10.1016/j.jacc.2018.12.054.

[8] R. Cau, F. Pisu, J. S. Suri, L. Mannelli, M. Scaglione, S. Masala, and L. Saba, "Artificial Intelligence Applications in Cardiovascular Magnetic Resonance Imaging: Are We on the Path to Avoiding the Administration of Contrast Media?," Diagnostics, vol. 13, p. 2061, 2023, doi: https://doi.org/10.3390/diagnostics13122061.

[9] Y. -F. Li, L. -Z. Guo and Z. -H. Zhou, "Towards Safe Weakly Supervised Learning," in IEEE Transactions on Pattern Analysis and Machine Intelligence, vol. 43, no. 1, pp. 334-346, 1 Jan. 2021, doi: https://doi.org/10.1109/TPAMI.2019.2922396.

[10] Acosta, J.N., Falcone, G.J., Rajpurkar, P. et al. Multimodal biomedical AI. Nat Med 28, 1773–1784 (2022), doi: https://doi.org/10.1038/s41591-022-01981-2.

[11] T. Leiner, D. Rueckert, A. Suinesiaputra, B. Baeßler, R. Nezafat, I. Išgum, and A. A. Young, "Machine learning in cardiovascular magnetic resonance: basic concepts and applications," Journal of Cardiovascular Magnetic Resonance, vol. 21, no. 1, p. 61, 2019, doi: https://doi.org/10.1186/s12968-019-0575-y.

[12] L. Faes, D. A. Sim, M. van Sweden, U. Held, P. M. Bossuyt, and L. M. Bachmann, "Artificial Intelligence and Statistics: Just the Old Wine in New Wineskins?," Frontiers in Digital Health, vol. 4, 2022, doi: https://doi.org/10.3389/fdgth.2022.833912.

[13] M. Islam and S. A. Karim, "Enhanced Flower Recognition via Transfer Learning with ResNet-50," International Journal of Scientific Research and Engineering Trends, vol. 10, pp. 2395–566, Nov. 2024, doi: https://doi.org/10.61137/ijsret.vol.10.issue6.341.

[14] H. S. R. Rajula, G. Verlato, M. Manchia, N. Antonucci, and V. Fanos, "Comparison of Conventional Statistical Methods with Machine Learning in Medicine: Diagnosis, Drug Development, and Treatment," Medicina, vol. 56, p. 455, 2020, doi: https://doi.org/10.3390/medicina56090455.

[15] C. Antoniades and E. K. Oikonomou, "Artificial intelligence in cardiovascular imaging—principles, expectations, and limitations," European Heart Journal, vol. 45, no. 15, pp. 1322–1326, Apr. 2024.doi: https://doi.org/10.1093/eurheartj/ehab678.

[16] R. K. E. Bellamy et al., "AI Fairness 360: An extensible toolkit for detecting and mitigating algorithmic bias," in IBM Journal of Research and Development, vol. 63, no. 4/5, pp. 4:1-4:15, 1 July-Sept. 2019, doi: https://doi.org/10.1147/JRD.2019.2942287

[17] R. K. E. Bellamy et al., "AI Fairness 360: An extensible toolkit for detecting and mitigating algorithmic bias," in IBM Journal of Research and Development, vol. 63, no. 4/5, pp. 4:1-4:15, 1 July-Sept. 2019, doi: https://doi.org/10.1147/JRD.2019.2942287

[18] W. Dieterich, C. Mendoza, and T. Brennan, "Demonstrating Accuracy, Equity, and Predictive Parity: Performance of the COMPAS Risk Scales in Broward County," Northpointe Inc. Research Department, Jul. 8, 2016, doi: https://doi.org/10.1002/9781119184256.ch3.

[19] J. M. John-Mathews, D. Cardon, and C. Balagué, "From Reality to World: A Critical Perspective on AI Fairness," Journal of Business Ethics, vol. 178, pp. 945–959, 2022, doi: https://doi.org/10.1007/s10551-022-05055-8.

[20] H. Van Kolfschooten, "EU regulation of artificial intelligence: Challenges for patients' rights," Common Market Law Review, vol. 59, no. 1, pp. 81–112, 2022, doi: https://doi.org/10.1053/j.akdh.2022.11.002 .

[21] R. Rodrigues, "Legal and human rights issues of AI: Gaps, challenges and vulnerabilities," Journal of Responsible Technology, vol. 4, p. 100005, 2020, doi: https://doi.org/10.1016/j.jrt.2020.100005.

[22] C.G. Filippi, J.M. Stein, Z. Wang, S. Bakas, Y. Liu, P.D. Chang, Y. Lui, C. Hess, D.P. Barboriak, A.E. Flanders, M. Wintermark, G. Zaharchuk and O. Wu American Journal of Neuroradiology November 2023, 44 (11) 1242-1248; doi: https://doi.org/10.3174/ajnr.A7963.

[23] R. Cau et al., "Atrial Strain by Feature-Tracking Cardiac Magnetic Resonance Imaging in Takotsubo Cardiomyopathy. Features, Feasibility, and Reproducibility," Canadian Association of Radiologists Journal, vol. 73, no. 3, pp. 573–580, 2022, doi: https://doi.org/10.1177/08465371211042.

[24] C.-J. Chao, J. Jeong, R. Arsanjani, K. Kim, C. Ayoub, M. Grogan, G. Kane, I. Banerjee, and J. K. Oh, "Title of the article," medRxiv, 2022, doi: https://doi.org/10.1101/2022.12.25.22283940.

[25] Y. Yu, X. Ling, Z. Xiong, and F. Yang, "Accurate Differential Diagnosis of Cardiomyopathy Phenotype Based on Multimodal AI Technology," Academic Journal of Science and Technology, vol. 13, no. 2, pp. 23–27, 2024, doi: https://doi.org/10.54097/3gk45b81.